11.05.2011 • NewsTeva Pharmaceutical IndustriesTevaBilanz

Teva Q1 Profit Up On Higher European Sales

Teva Pharmaceutical Industries, the world's largest generic drugmaker, met forecasts with a 14% rise in quarterly earnings on strong sales growth in Europe following last year's Ratiopharm acquisition.

Israel-based Teva, which last week announced a deal to acquire U.S. specialty drugmaker Cephalon for $6.8 billion, posted first-quarter earnings before certain items of $1.04 per share. Sales rose 12.1% to $4.1 billion.

Teva was expected to earn $1.04 on revenue of $4.27 billion, according to a Thomson Reuters I/B/E/S poll.

Sales of Copaxone, the leading multiple sclerosis treatment with a global market share of 31%, increased 14% to $907 million.

Teva reiterated its outlook, excluding anticipated acquisitions, for 2011 revenue of $18.5-$19 billion and earnings per share excluding items of $4.90-$5.20. Teva declared a dividend of 0.80 shekel.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.